These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22681401)

  • 1. Development of a model for functional studies of ABCG2 (breast cancer resistance protein) efflux employing a standard BeWo clone (B24).
    Crowe A; Keelan JA
    Assay Drug Dev Technol; 2012 Oct; 10(5):476-84. PubMed ID: 22681401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.
    Ceckova M; Libra A; Pavek P; Nachtigal P; Brabec M; Fuchs R; Staud F
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):58-65. PubMed ID: 16445700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efflux transporter mRNA expression profiles in differentiating JEG-3 human choriocarcinoma cells as a placental transport model.
    Ikeda K; Yamasaki K; Homemoto M; Yamaue S; Ogawa M; Nakao E; Fukunaga Y; Nakanishi T; Utoguchi N; Myotoku M; Hirotani Y
    Pharmazie; 2012 Jan; 67(1):86-90. PubMed ID: 22393837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).
    Meyer zu Schwabedissen HE; Grube M; Dreisbach A; Jedlitschky G; Meissner K; Linnemann K; Fusch C; Ritter CA; Völker U; Kroemer HK
    Drug Metab Dispos; 2006 Apr; 34(4):524-33. PubMed ID: 16415123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oxygen on multidrug resistance in the first trimester human placenta.
    Lye P; Bloise E; Dunk C; Javam M; Gibb W; Lye SJ; Matthews SG
    Placenta; 2013 Sep; 34(9):817-23. PubMed ID: 23790363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic and Dietary Regulation of Glyburide Efflux by the Human Placental Breast Cancer Resistance Protein Transporter.
    Bircsak KM; Gupta V; Yuen PY; Gorczyca L; Weinberger BI; Vetrano AM; Aleksunes LM
    J Pharmacol Exp Ther; 2016 Apr; 357(1):103-13. PubMed ID: 26850786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a confluent monolayer model with human primary trophoblast cells: novel insights into placental glucose transport.
    Huang X; Lüthi M; Ontsouka EC; Kallol S; Baumann MU; Surbek DV; Albrecht C
    Mol Hum Reprod; 2016 Jun; 22(6):442-56. PubMed ID: 26931579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2).
    Shen H; Lee FY; Gan J
    J Pharmacol Exp Ther; 2011 May; 337(2):423-32. PubMed ID: 21262849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between riluzole and ABCG2/BCRP transporter.
    Milane A; Vautier S; Chacun H; Meininger V; Bensimon G; Farinotti R; Fernandez C
    Neurosci Lett; 2009 Mar; 452(1):12-6. PubMed ID: 19146924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
    González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
    J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction.
    Evseenko DA; Murthi P; Paxton JW; Reid G; Emerald BS; Mohankumar KM; Lobie PE; Brennecke SP; Kalionis B; Keelan JA
    FASEB J; 2007 Nov; 21(13):3592-605. PubMed ID: 17595345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jadomycins are cytotoxic to ABCB1-, ABCC1-, and ABCG2-overexpressing MCF7 breast cancer cells.
    Issa ME; Hall SR; Dupuis SN; Graham CL; Jakeman DL; Goralski KB
    Anticancer Drugs; 2014 Mar; 25(3):255-69. PubMed ID: 24231527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.